BOSTON, Massachusetts, October 29, 2026
CereVasc, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) application to evaluate its eShunt System in patients with early symptomatic Alzheimer’s disease (AD). The regulatory authorization allows the company to investigate a minimally invasive medical device approach designed to influence the movement of cerebrospinal fluid (CSF) and potentially support the brain’s natural clearance of neurotoxins associated with Alzheimer’s disease. The announcement represents an important development in CereVasc’s clinical research programme and introduces a different investigational approach to a disease for which new treatment strategies remain an important medical priority. The company is developing the eShunt System as an endovascular device intended to divert CSF into the venous system. The planned investigation will examine whether increasing CSF cycling through this approach could have a role in the management of early symptomatic Alzheimer’s disease.
FDA IDE Approval Enables Clinical Evaluation of eShunt
The FDA’s approval of the IDE application provides regulatory authorization for CereVasc to evaluate the eShunt System in a clinical investigation involving patients with early symptomatic Alzheimer’s disease. An Investigational Device Exemption allows an investigational medical device to be studied in people under specified regulatory and clinical conditions. It is not the same as FDA marketing approval, and it does not establish that a device is safe and effective for routine clinical use. CereVasc’s eShunt System is designed as a minimally invasive endovascular shunt that diverts cerebrospinal fluid to the venous system. CSF is a clear fluid that surrounds the brain and spinal cord and plays important roles in protecting and maintaining the central nervous system. The company intends to investigate whether modifying CSF flow and increasing CSF cycling may support the brain’s natural processes for clearing neurotoxins associated with Alzheimer’s disease. This proposed mechanism is the focus of the clinical evaluation; its potential clinical benefits will need to be demonstrated through research. The authorization therefore represents permission to investigate the approach rather than evidence that the device can prevent, slow or treat Alzheimer’s disease.
eShunt System Investigates Cerebrospinal Fluid Clearance
The eShunt System uses a specialised percutaneous transvenous-transdural approach to access the central nervous system. Its design includes an endovascularly implantable CSF shunt and delivery components intended to provide a less invasive alternative to conventional surgical approaches for certain communicating hydrocephalus conditions. In the Alzheimer’s disease investigation, CereVasc plans to examine whether diverting CSF into the venous system can increase CSF cycling and potentially assist the brain’s natural clearance pathways. The scientific rationale centres on the role of fluid movement and waste-clearance mechanisms in neurological health. However, the relationship between CSF circulation, neurotoxin clearance and Alzheimer’s disease progression is complex. Clinical evidence will be necessary to establish whether the proposed device-based intervention produces meaningful benefits for patients. The company has not announced clinical results from this Alzheimer’s disease investigation in the announcement. Researchers and healthcare professionals will therefore need to assess the study findings before drawing conclusions about the treatment’s effectiveness, safety profile or potential place in future care.
CereVasc Expands Its Clinical Development in Neurological Diseases
CereVasc is a clinical-stage medical device company focused on developing minimally invasive treatments for neurological diseases. Its eShunt System is also being evaluated for normal pressure hydrocephalus (NPH), a condition associated with an abnormal accumulation of cerebrospinal fluid in the brain. The company recently completed enrolment in STRIDE, its pivotal randomized controlled trial, evaluating the eShunt System for NPH. This ongoing development programme provides additional clinical experience with the device platform, although findings from one indication cannot automatically establish safety or effectiveness in another. Commenting on the Alzheimer’s disease authorization, Tony Kingsley, President and Chief Executive Officer of CereVasc, said the milestone provides an opportunity to build on the company’s clinical experience and work with leading Alzheimer’s experts. Dr. Adnan Siddiqui, Vice Chairman of Neurosurgery at SUNY Buffalo’s Jacobs School of Medicine and CEO of the Jacobs Institute, also highlighted the importance of investigating approaches that may improve the brain’s clearance pathways.
Alzheimer’s disease is the most common cause of dementia and affects millions of people and families worldwide. The need for innovative research remains significant as healthcare systems face growing demands associated with ageing populations and neurological disorders. CereVasc’s FDA IDE authorization marks a step forward in investigating a device-based approach to early symptomatic Alzheimer’s disease. Future clinical findings will be important in determining whether CSF diversion through the eShunt System can offer a meaningful therapeutic benefit. The device remains investigational, and its safety and effectiveness have not yet been established. It is not approved for commercial sale in the United States or other markets.
Source: CereVasc press release



